GC
MRNS

Grimes & Company’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Grimes & Company’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33,609
Closed -$59.2K – 402
2024
Q3 		$59.2K Hold
33,609
– – ﹤0.01% 357
2024
Q2 		$39.3K Buy
33,609
+60
+0.2% +$150 ﹤0.01% 342
2024
Q1 		$303K Sell
33,549
-751
-2% -$7.3K 0.01% 269
2023
Q4 		$373K Sell
34,300
-561
-2% -$4.2K 0.01% 245
2023
Q3 		$281K Buy
34,861
+110
+0.3% +$915 0.01% 248
2023
Q2 		$377K Hold
34,751
– – 0.01% 225
2023
Q1 		$240K Buy
34,751
+122
+0.4% +$765 0.01% 257
2022
Q4 		$138K Hold
34,629
– – 0.01% 275
2022
Q3 		$230K Buy
34,629
+750
+2% +$4.62K 0.01% 245
2022
Q2 		$164K Buy
33,879
+1,114
+3% +$6.78K 0.01% 260
2022
Q1 		$306K Buy
32,765
+7,085
+28% +$70.4K 0.02% 238
2021
Q4 		$305K Sell
25,680
-3,448
-12% -$39.8K 0.01% 239
2021
Q3 		$331K Buy
29,128
+2,697
+10% +$37.1K 0.01% 229
2021
Q2 		$474K Buy
26,431
+2,606
+11% +$41.9K 0.02% 203
2021
Q1 		$369K Buy
23,825
+11,575
+94% +$167K 0.02% 214
2020
Q4 		$149K Buy
12,250
+1,000
+9% +$13.9K 0.01% 258
2020
Q3 		$145K Buy
11,250
+7,125
+173% +$61.5K 0.01% 237
2020
Q2 		$42K Buy
+4,125
New +$37.9K ﹤0.01% 244

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Grimes & Company's MRNS Position: Q4 2024 in Review

Grimes & Company sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 33,609 shares — an estimated $59.2K sold.

Grimes & Company first reported a position in MRNS in Q2 2020 and held it in 18 quarters. The position peaked at $474K in Q2 2021. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Grimes & Company reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Grimes & Company sold 33,609 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $59.2K.
  • Grimes & Company first reported a position in Marinus Pharmaceuticals, Inc in Q2 2020 and held it in 18 quarters.
  • Grimes & Company's Marinus Pharmaceuticals, Inc position peaked at $474K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Grimes & Company's 13F filing for Q4 2024, filed 21 Jan 2025.